CY1123576T1 - Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib - Google Patents

Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib

Info

Publication number
CY1123576T1
CY1123576T1 CY20201101084T CY201101084T CY1123576T1 CY 1123576 T1 CY1123576 T1 CY 1123576T1 CY 20201101084 T CY20201101084 T CY 20201101084T CY 201101084 T CY201101084 T CY 201101084T CY 1123576 T1 CY1123576 T1 CY 1123576T1
Authority
CY
Cyprus
Prior art keywords
napi
derivatives useful
thiophene derivatives
fused thiophene
iib
Prior art date
Application number
CY20201101084T
Other languages
English (en)
Inventor
David Andrew Coates
Kevin Robert Fales
Jeffrey Alan Peterson
Jeffrey Michael Schkeryantz
Quanrong Shen
Matthew John Valli
John Rowley WETTERAU II
Dariusz Stanislaw WODKA
Yangping XU
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1123576T1 publication Critical patent/CY1123576T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

Η εφεύρεση παρέχει ενώσεις του τύπου (Α), φαρμακευτικώς αποδεκτά άλατα, φαρμακευτικές συνθέσεις αυτών, και μεθόδους χρησιμοποίησης αυτών των ενώσεων, αλάτων, ή συνθέσεων για τη θεραπεία της υπερ-φωσφαταιμίας, της χρόνιας νεφροπάθειας, ή/και της καρδιαγγειακής νόσου που συνδέεται με χρόνια νεφροπάθεια.
CY20201101084T 2016-08-15 2020-11-16 Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib CY1123576T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662375169P 2016-08-15 2016-08-15
PCT/US2017/045843 WO2018034883A1 (en) 2016-08-15 2017-08-08 Condensed thiophene derivatives useful as napi-iib inhibitors

Publications (1)

Publication Number Publication Date
CY1123576T1 true CY1123576T1 (el) 2022-03-24

Family

ID=59677343

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101084T CY1123576T1 (el) 2016-08-15 2020-11-16 Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib

Country Status (24)

Country Link
US (1) US10934280B2 (el)
EP (1) EP3497091B1 (el)
JP (1) JP6653410B2 (el)
KR (1) KR102266143B1 (el)
CN (1) CN109563070B (el)
AU (1) AU2017312783B2 (el)
BR (1) BR112019000929A2 (el)
CA (1) CA3033628C (el)
CY (1) CY1123576T1 (el)
DK (1) DK3497091T3 (el)
EA (1) EA037376B1 (el)
ES (1) ES2830444T3 (el)
HR (1) HRP20202025T1 (el)
HU (1) HUE052351T2 (el)
IL (1) IL264785B (el)
LT (1) LT3497091T (el)
MX (1) MX2019001781A (el)
PL (1) PL3497091T3 (el)
PT (1) PT3497091T (el)
RS (1) RS61165B1 (el)
SA (1) SA519401049B1 (el)
SI (1) SI3497091T1 (el)
WO (1) WO2018034883A1 (el)
ZA (1) ZA201900305B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202105190SA (en) * 2018-11-19 2021-06-29 11949098 Canada Inc 4,5,6,7-tetrahydro-l-benzothiophene modulators of retinoic acid receptor related (rar) orphan nuclear receptors (rors)
CN113784956A (zh) * 2019-05-16 2021-12-10 伊莱利利公司 钠-氢交换体3抑制剂化合物
AU2022288895A1 (en) 2021-06-08 2024-01-18 Chugai Seiyaku Kabushiki Kaisha Formulation containing dihydropyridazine-3,5-dione derivative
AR126060A1 (es) 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
WO2023219127A1 (ja) * 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2565190E (pt) * 2010-04-28 2015-08-24 Astellas Pharma Inc Composto de tetra-hidrobenzotiofeno
JP6020460B2 (ja) * 2011-10-27 2016-11-02 アステラス製薬株式会社 アミノアルキル置換ｎ−チエニルベンズアミド誘導体
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
CN105658635B (zh) * 2014-08-22 2019-03-08 江苏恒瑞医药股份有限公司 噻吩并环烷基或噻吩并杂环基类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
KR20190026895A (ko) 2019-03-13
EA201990095A1 (ru) 2019-07-31
JP6653410B2 (ja) 2020-02-26
PT3497091T (pt) 2020-11-30
SI3497091T1 (sl) 2020-11-30
AU2017312783A1 (en) 2019-01-24
US20200031813A1 (en) 2020-01-30
HUE052351T2 (hu) 2021-04-28
HRP20202025T1 (hr) 2021-02-19
CA3033628A1 (en) 2018-02-22
PL3497091T3 (pl) 2021-02-08
KR102266143B1 (ko) 2021-06-17
MX2019001781A (es) 2019-07-04
IL264785B (en) 2021-04-29
EP3497091A1 (en) 2019-06-19
NZ750153A (en) 2021-01-29
SA519401049B1 (ar) 2021-07-14
CA3033628C (en) 2021-01-12
EA037376B1 (ru) 2021-03-22
RS61165B1 (sr) 2021-01-29
CN109563070A (zh) 2019-04-02
DK3497091T3 (da) 2020-10-19
CN109563070B (zh) 2021-02-26
AU2017312783B2 (en) 2020-02-06
WO2018034883A1 (en) 2018-02-22
ZA201900305B (en) 2020-12-23
ES2830444T3 (es) 2021-06-03
JP2019527734A (ja) 2019-10-03
EP3497091B1 (en) 2020-10-07
LT3497091T (lt) 2020-12-28
BR112019000929A2 (pt) 2019-07-09
US10934280B2 (en) 2021-03-02

Similar Documents

Publication Publication Date Title
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
CY1120903T1 (el) Ενωσεις αμινοπυριδυλοξυπυραζολιου
CY1123576T1 (el) Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
CY1124669T1 (el) ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1122279T1 (el) Ενωσεις ναφθυριδινης αναστολεις κινασης jak
CY1120662T1 (el) Παραγωγα πυρρολαμιδιου υποκατεστημενου γλυοξαμιδιου και η χρηση αυτων ως φαρμακων για τη θεραπευτικη αντιμετωπιση της ηπατιτιδας β
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CY1123417T1 (el) Παραγωγα τετρα�δροϊσοκινολινης
CY1123801T1 (el) Παραγωγα αρωματικου σουλφοναμιδιου
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201691421A1 (ru) Гетероарилы и их применение
CY1125047T1 (el) Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης
EA201790765A1 (ru) Производные спиродиамина в качестве ингибиторов альдостерон-синтазы
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
CY1121746T1 (el) Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης
EA201791304A1 (ru) Производные изохинолина для лечения вич
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
CY1121596T1 (el) Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений